Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
- Borderline Ovarian Mucinous Tumor
- Ovarian Mucinous Cystadenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Stage IA Fallopian Tube Cancer AJCC v6 and v7
- Stage IA Ovarian Cancer AJCC v6 and v7
- Stage IB Fallopian Tube Cancer AJCC v6 and v7
- Stage IB Ovarian Cancer AJCC v6 and v7
- Stage IC Fallopian Tube Cancer AJCC v6 and v7
- Stage IC Ovarian Cancer AJCC v6 and v7
- Stage IIA Fallopian Tube Cancer AJCC v6 and v7
- Stage IIA Ovarian Cancer AJCC V6 and v7
- Stage IIB Fallopian Tube Cancer AJCC v6 and v7
- Stage IIB Ovarian Cancer AJCC v6 and v7
- Stage IIC Fallopian Tube Cancer AJCC v6 and v7
- Stage IIC Ovarian Cancer AJCC v6 and v7
- Stage IIIA Fallopian Tube Cancer AJCC v7
- Stage IIIA Ovarian Cancer AJCC v6 and v7
- Stage IIIB Fallopian Tube Cancer AJCC v7
- Stage IIIB Ovarian Cancer AJCC v6 and v7
- Stage IIIC Fallopian Tube Cancer AJCC v7
- Stage IIIC Ovarian Cancer AJCC v6 and v7
- Stage IV Fallopian Tube Cancer AJCC v6 and v7
- Stage IV Ovarian Cancer AJCC v6 and v7
Interventions
- BIOLOGICAL: Bevacizumab
- DRUG: Capecitabine
- DRUG: Carboplatin
- OTHER: Laboratory Biomarker Analysis
- DRUG: Oxaliplatin
- DRUG: Paclitaxel
- OTHER: Quality-of-Life Assessment
Sponsor
National Cancer Institute (NCI)
Collaborators